HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, has announced its plans to voluntarily delist from the Nasdaq Capital Market and deregister its common stock under the Securities Exchange Act of 1934. This decision comes in light of the impending Asset Sale to Gilead Sciences, Inc., which involves the transfer of assets related to HOOKIPA's HB-400 and HB-500 programs. Following the Asset Sale, HOOKIPA intends to dissolve and liquidate, subject to stockholder approval at a special meeting scheduled for July 29, 2025. The company cites the economic burden of ongoing reporting requirements as a factor in its decision, as compliance would diminish the assets available for distribution to stockholders. If approved, HOOKIPA plans to file a Certificate of Dissolution with the Delaware Secretary of State, marking the commencement of its winding up and liquidation process.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。